Amrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients.
Sign Up to like & getrecommendations! Published in 2025 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaf140
Abstract: BACKGROUND Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study… read more here.
Keywords: dose; amrubicin monotherapy; elderly patients; refractory relapsed ... See more keywords
Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2025 at "AntiCancer Research"
DOI: 10.21873/anticanres.17461
Abstract: Background/Aim: Amrubicin is recognized as a second-line treatment for refractory small-cell lung cancer (SCLC) and is administered immediately after chemotherapy; however, it has not been evaluated in patients with recurrent SCLC following chemoradiotherapy (CRT). This… read more here.
Keywords: amrubicin; amrubicin monotherapy; efficacy; crt ... See more keywords